Back to results
US 2025/0049737 A1Published application
Lauflumide and derivatives thereof for treating chronic fatigue syndrome and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
AssigneeNLS Pharmaceutics AG
InventorsEric KONOFAL, Emily Samuela TURILLI
Life of this patent
Estimating the term…
Abstract
The invention concerns a compound of formula (I), wherein R1=halogen atom selected in the group consisting of: F, Cl, Br, I, and R2=H or OH, or a pharmaceutically acceptable isomer, salt and/or solvate thereof, for use in preventing and/or treating chronic fatigue syndrome.
Claims14
1-9. (canceled)
A method of prevention and/or treatment of chronic fatigue syndrome comprising the administration of a compound of formula (I)
- with R1=a halogen atom selected in the group consisting of F, Cl, Br, and I, and R2=H or OH,
- or a pharmaceutically acceptable isomer, salt, and/or solvate thereof, to a patient in need thereof.
Dependencies are inferred from the claim text.